knowledge -WSS

knowledge

author：explore 2025-10-02 18:46:47 - browse：48

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： What to know about the judge who will handle the Trump case

focus

WSS

Diversify hospital leadership teams to protect BIPOC patient health

Dozens dead from Maui wildfires: What we know about the victims

Health AI: on the border between health care and tech

Just how powerful is the placebo effect?

The Sacklers, horror, and ‘The Fall of the House of Usher’

Free speech concerns arise in wake of journal editor Eisen's firing

knowledge

knowledge

focus

Drug repurposing or repositioning? The language matters

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Virginia high school admissions case could be legal follow

Illinois Supreme Court finds assault weapons ban constitutional

Walensky prepares to leave CDC — and Congress — behind

Idaho college killings prosecutors challenge defense's grand jury claims

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Dozens dead from Maui wildfires: What we know about the victims

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

leisure time

After Optum profits sink, UnitedHealth makes changes

FDA approves Recor Medical high blood pressure device

Illinois Supreme Court finds assault weapons ban constitutional

Schizophrenia gene found to be linked to cells' energy dysfunction

Illinois Supreme Court finds assault weapons ban constitutional

Illumina slashes 2023 revenue projections yet again

knowledge

focus

leisure time

explore